Asian Flush Gene Variant Enhances Cellular Immunogenicity of COVID-19 Vaccine: Prospective Observation in the Japanese General Population

• Published in: Vaccines (Basel) Vol. 12; no. 9; p. 1015
• Main Authors: Bogahawaththa, Sudarma, Hara, Megumi, Furukawa, Takuma, Iwasaka, Chiharu, Sawada, Takeshi, Yamada, Goki, Tokiya, Mikiko, Kitagawa, Kyoko, Miyake, Yasunobu, Kido, Mizuho Aoki, Hirota, Yoshio, Matsumoto, Akiko
• Format: Journal Article
• Language: English
• Published: Switzerland MDPI AG 05.09.2024; MDPI
• Subjects: Alcohol; Aldehyde dehydrogenase; ALDH2; Allergic diseases; Allergies; Analysis; Cell-mediated immunity; Cellular immunity; Cohort analysis; COVID-19; COVID-19 vaccines; Disease transmission; Drug development; Drug dosages; Enzyme-linked immunosorbent assay; enzyme-linked immunospot; Enzymes; Ethanol; Genetic variation; Immune response; Immune response (cell-mediated); Immune response (humoral); Immune system; Immunity; Immunity (Disease); Immunogenicity; Immunoglobulin G; Influence; Mutation; Observational studies; Pandemics; Peptides; Questionnaires; rs671; Severe acute respiratory syndrome coronavirus 2; T cell; Vaccines; Viral diseases; γ-Interferon; Japan; United States > US; Germany; COVID-19; enzyme-linked immunospot; ALDH2; rs671; T cell; cellular immunity
• ISSN: 2076-393X; 2076-393X
• DOI: 10.3390/vaccines12091015

We previously reported a reduced humoral immune response to the COVID-19 vaccines. Subsequently, we observed a lower susceptibility to COVID-19 in individuals carrying the rs671 variant through a web-based retrospective survey. Based on these findings, we hypothesized that rs671 variant was beneficial for cellular immunity against COVID-19. Using the IFN-γ enzyme-linked immunospot (ELISPOT) assay, we assessed cellular immunity before and after COVID-19 vaccination in two subcohorts of a previously reported cohort. Subcohort 1 (26 participants) had six repeated observations at baseline after one to three doses, whereas subcohort 2 (19 participants) had two observations before and after the third dose. ELISPOT counts at six months after the second dose increased from baseline in carriers of the rs671 variant but not in non-carriers. A positive effect of rs671 on ELISPOT counts was estimated using a mixed model (183 observations from 45 participants), including the random effect of subcohort, repeated measures, and fixed effects of vaccine type, age, sex, height, lifestyle, steroid use, and allergic disease. There was no association between ELISPOT counts and specific IgG levels, suggesting a limitation in estimating protective potential by humoral response. Our sequential observational studies suggest a beneficial effect of the rs671 variant in SARS-CoV-2 infection via enhanced cellular immune response, providing a potential basis for optimizing preventive measures and drug development.